CORT Stock Analysis: Corcept Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 12.790m USD | 12M Return: 55% | US2183521028 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 123M
EPS Trend: -59.7%
Qual. Beats: 1
Rev. Trend: 97.3%
Qual. Beats: 1
Warnings
Tailwinds
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Corcept Therapeutics Incorporated is a U.S.-based biopharmaceutical company that develops medications targeting severe endocrinologic, oncologic, metabolic, and neurologic disorders. Its flagship commercial product, Korlym, is an oral therapy approved to treat hyperglycemia in adult patients with endogenous Cushings syndrome who also have type 2 diabetes or glucose intolerance and are not candidates for surgery. The company is headquartered in Redwood City, California, and has been incorporated since 1998, trading on NASDAQ under the ticker CORT since its 2004 IPO.
Corcepts pipeline centers on a portfolio of proprietary selective cortisol modulators, including relacorilant (for hypercortisolism), miricorilant (currently in a Phase 1b trial for metabolic dysfunction-associated steatohepatitis, or MASH), and candidates such as nenocorilant and dazucorilant being explored for Lou Gehrigs disease (ALS). As a clinical-stage biopharma with a niche specialty drug franchise, Corcept operates in the GICS Pharmaceuticals sub-industry, where its business model combines revenue from a single approved orphan-indication product with ongoing R&D investment across multiple therapeutic areas driven by cortisol-receptor science.
- Korlym revenue growth sustains quarterly beats
- Relacorilant Phase 3 results in Cushings catalyst
- Generics and Isturisa competition pressure Korlym pricing
| Net Income: 54.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA -10.46 > 1.0 |
| NWC/Revenue: 34.41% < 20% (prev 41.68%; Δ -7.27% < -1%) |
| CFO/TA 0.12 > 3% & CFO 109.7m > Net Income 54.9m |
| Net Debt (-298.8m) to EBITDA (8.82m): -33.86 < 3 |
| Current Ratio: 2.86 > 1.5 & < 3 |
| Outstanding Shares: last quarter (118.4m) vs 12m ago -1.74% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 98.30% > 50% (prev 89.32%; Δ 8.98% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.32 (Total Current Assets 439.7m - Total Current Liabilities 153.8m) / Total Assets 888.7m |
| B: 0.74 (Retained Earnings 654.6m / Total Assets 888.7m) |
| C: 0.01 (EBIT TTM 6.41m / Avg Total Assets 845.2m) |
| D: 3.86 (Book Value of Equity 705.8m / Total Liabilities 182.9m) |
| Altman-Z'' = 8.61 = AAA |
| DSRI: 0.97 (Receivables 76.9m/68.7m, Revenue 830.8m/716.1m) |
| GMI: 1.00 (GM 98.37% / 98.30%) |
| AQI: 1.12 (AQ_t 0.49 / AQ_t-1 0.44) |
| SGI: 1.16 (Revenue 830.8m / 716.1m) |
| TATA: -0.06 (NI 54.9m - CFO 109.7m) / TA 888.7m) |
| Beneish M = -2.87 (Cap -4..+1) = A |
As of August 08, 2026, the stock is trading at USD 110.77 with a total of 730,925 shares traded. Over the past week, the price has changed by -3.25%, over one month by +17.79%, over three months by +116.98% and over the past year by +54.97%.
Current recommended Stop Loss: 104.80 (which is 5.4% or 1.1 ATR below the current price).
Corcept Therapeutics has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy CORT.
- StrongBuy: 4
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 117.8 | 6.3% |
P/E Trailing = 262.9334
P/E Forward = 113.6364
P/S = 16.6302
P/B = 15.6403
P/EG = 0.813
Revenue TTM = 830.8m USD
EBIT TTM = 6.41m USD
EBITDA TTM = 8.82m USD
Long Term Debt = 7.50m USD (estimated: total debt 9.42m - short term 1.92m)
Short Term Debt = 1.92m USD (from shortTermDebt, last quarter)
Debt = 9.42m USD (from shortLongTermDebtTotal, last quarter) (leases 9.42m already included)
Net Debt = -298.8m USD (calculated: Debt 9.42m - CCE 308.2m)
Enterprise Value = 12.5b USD (12.8b + Debt 9.42m - CCE 308.2m)
Interest Coverage Ratio = unknown (Ebit TTM 6.41m / Interest Expense TTM 0.0)
EV/FCF = 116.8x (Enterprise Value 12.5b / FCF TTM 106.9m)
FCF Yield = 0.86% (FCF TTM 106.9m / Enterprise Value 12.5b)
FCF Margin = 12.87% (FCF TTM 106.9m / Revenue TTM 830.8m)
Net Margin = 6.61% (Net Income TTM 54.9m / Revenue TTM 830.8m)
Gross Margin = unknown ((Revenue TTM 830.8m - Cost of Revenue TTM 14.1m) / Revenue TTM)
Tobins Q-Ratio = 14.06 (Enterprise Value 12.5b / Total Assets 888.7m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 9.42m)
Taxrate = 6.41% (2.94m / 45.9m)
NOPAT = 5.99m (EBIT 6.41m * (1 - 6.41%))
Current Ratio = 2.86 (Total Current Assets 439.7m / Total Current Liabilities 153.8m)
Debt / Equity = 0.01 (Debt 9.42m / totalStockholderEquity, last quarter 705.8m)
Debt / EBITDA = -33.86 (Net Debt -298.8m / EBITDA 8.82m)
Debt / FCF = -2.79 (Net Debt -298.8m / FCF TTM 106.9m)
Total Stockholder Equity = 655.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 6.49% (Net Income 54.9m / Total Assets 888.7m)
RoE = 8.37% (Net Income TTM 54.9m / Total Stockholder Equity 655.9m)
RoCE = 0.97% (EBIT 6.41m / Capital Employed (Equity 655.9m + L.T.Debt 7.50m))
RoIC = 0.86% (NOPAT 5.99m / Invested Capital 695.3m)
WACC = 12.19% (E(12.8b)/V(12.8b) * Re(12.20%) + D(9.42m)/V(12.8b) * Rd(0.0%) * (1-Tc(0.06)))
Discount Rate = 12.20% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 21.05 | Cagr: 3.35%
[DCF] Terminal Value 60.22% ; FCFF base≈136.3m ; Y1≈119.5m ; Y5≈96.5m
[DCF] Fair Price = 11.59 (EV 954.0m - Net Debt -298.8m = Equity 1.25b / Shares 108.1m; r=12.19% [WACC]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: -59.66 | EPS CAGR: -24.03% | SUE: 3.58 | # QB: 1
Revenue Correlation: 97.27 | Revenue CAGR: 23.84% | SUE: 1.79 | # QB: 1
EPS current Quarter (2026-09-30): EPS=0.36 | Chg30d=+42.12% | Revisions=+17% | Analysts=2
EPS current Year (2026-12-31): EPS=0.81 | Chg30d=+67.18% | Revisions=+17% | GrowthEPS=-0.6% | GrowthRev=+38.3%
EPS next Year (2027-12-31): EPS=4.75 | Chg30d=+90.25% | Revisions=+17% | GrowthEPS=+482.4% | GrowthRev=+50.1%
[Analyst] Revisions Ratio: +25% (up=6, down=3)